China BCT Pharmacy Group, Inc. (CNBI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China BCT Pharmacy Group, Inc. (CNBI) trades at $0.00 with AI Score 41/100 (Grade C). China BCT Pharmacy Group, Inc. Market cap: $686,778, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CNBI: CNBI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNBI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNBI: the 1 perspectives are evenly split.
How is this calculated? →China BCT Pharmacy Group, Inc. (CNBI) Healthcare & Pipeline Overview
China BCT Pharmacy Group, Inc. operates as a comprehensive pharmaceutical enterprise in China, integrating distribution, retail pharmacy under the 'Baicaotang' brand, and manufacturing of generic and clinical drugs via its 'Asio' division. With 196 pharmacies and an inventory of approximately 8,000 items, the company serves a broad client base across the healthcare supply chain, primarily within Guangxi province.
What Is the Investment Thesis for CNBI?
China BCT Pharmacy Group, Inc. presents an integrated pharmaceutical business model within China, leveraging its three core divisions: distribution, retail, and manufacturing. The company's extensive network of 196 'Baicaotang' pharmacies and a diverse inventory of approximately 8,000 items position it to capitalize on the growing demand for pharmaceutical products in China. With a profit margin of 8.7% and a gross margin of 20.1%, the company demonstrates operational efficiency. The 'Asio' manufacturing division contributes to value creation through proprietary generic and clinical pharmaceuticals. However, the company's status as an OTC Other-listed stock, with a market capitalization of $686,778 and a low share price of $0.0002, signals significant liquidity and financial resource limitations, alongside heightened risks of delisting and limited transparency. Investors evaluating CNBI should consider its operational breadth against the substantial risks associated with its OTC market tier and micro-cap status.
Based on FMP financials and quantitative analysis
CNBI Key Highlights
- Market Capitalization: $686,778, indicating a micro-cap status with limited financial resources and inherent volatility.
- Profit Margin: 8.7%, reflecting the company's profitability from its integrated pharmaceutical operations across distribution, retail, and manufacturing.
- Gross Margin: 20.1%, demonstrating the efficiency of its procurement, manufacturing, and sales processes within the healthcare sector.
- Employee Base: 1,677 employees, supporting its extensive operations across three distinct pharmaceutical divisions in China.
- Retail Presence: 196 directly owned 'Baicaotang' pharmacies, primarily concentrated in Guangxi province, forming a significant consumer touchpoint and distribution channel.
Who Are CNBI's Competitors?
CNBI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNBI's Key Strengths?
- Comprehensive pharmaceutical enterprise with three distinct divisions: distribution, retail, and manufacturing.
- Extensive retail network of 196 directly owned 'Baicaotang' pharmacies, primarily in Guangxi province.
- Diverse inventory of approximately 8,000 distinct items, including Western, Chinese, and OTC medicines.
- Proprietary manufacturing capabilities under the 'Asio' brand for generic and clinical pharmaceuticals.
- Established presence and operational experience within the Chinese pharmaceutical market.
What Are CNBI's Weaknesses?
- Trades on the OTC Other tier, indicating heightened risk and limited oversight.
- Very low market capitalization of $686,778 and share price of $0.0002, suggesting limited financial resources.
- Unknown disclosure status, potentially leading to a lack of transparency for investors.
- Limited liquidity due to its OTC listing, making it difficult to buy or sell shares.
- Negative Beta of -3.86, indicating unusual price movement relative to the market.
What Could Drive CNBI Stock Higher?
- Any public announcement of improved financial reporting or compliance that could lead to an upgrade in its OTC Markets tier.
- Strategic partnerships or collaborations that could expand its pharmaceutical distribution network or manufacturing capabilities.
- Continued expansion of its 'Baicaotang' retail pharmacy network into new regions, driving increased direct-to-consumer sales.
- Introduction of new generic or clinical pharmaceutical products from its 'Asio' manufacturing division, potentially boosting revenue streams.
- Increased demand for pharmaceutical products in China, which could positively impact sales across all three business segments.
What Are the Key Risks for CNBI?
- Significant risk of delisting from the OTC market due to its 'OTC Other' tier status and unknown disclosure level.
- Limited liquidity and high volatility due to its extremely low market capitalization and share price, making trading difficult.
- Intense competition within the highly regulated Chinese pharmaceutical market from larger, more established players.
- Regulatory changes or stricter enforcement in China's healthcare sector could negatively impact operations and profitability.
- Limited access to capital for funding growth initiatives or research and development due to its micro-cap and OTC status.
What Are the Growth Opportunities for CNBI?
- Growth opportunity 1: Expansion of the 'Baicaotang' Retail Pharmacy Network. With 196 directly owned pharmacies predominantly in Guangxi province, there is an opportunity to expand this network into other provinces within China. The growing urbanization and increasing disposable income in second and third-tier cities present new markets for healthcare products. Expanding the retail footprint could significantly increase direct consumer access and sales volume, leveraging the established brand recognition within its current operating regions. This expansion could target a timeline of 3-5 years, potentially tapping into a broader segment of China's estimated $200 billion retail pharmacy market.
- Growth opportunity 2: Diversification and Enhancement of Pharmaceutical Manufacturing. The 'Asio' brand currently manufactures generic and clinical pharmaceuticals, including treatments for inflammation, infections, oncology, cardiovascular, and hepatitis. There is a growth opportunity to invest in research and development for new generic drugs or biosimilars, or to expand into high-demand therapeutic areas such as chronic diseases or rare diseases. This could involve strategic partnerships or acquisitions to broaden the product portfolio and capture a larger share of China's pharmaceutical manufacturing market, which is projected to reach over $300 billion by 2027. This strategy would enhance product margins and reduce reliance on third-party suppliers.
- Growth opportunity 3: Broadening Pharmaceutical Distribution Reach and Client Base. The Pharmaceutical Distribution division currently supplies hospitals, retail drug stores, other wholesalers, clinics, medical centers, and individual consumers. A significant growth opportunity lies in expanding its distribution network to cover a wider geographic area beyond its current primary focus, potentially through strategic alliances with regional distributors or by establishing new logistical hubs. Furthermore, deepening relationships with existing institutional clients and securing new contracts with larger hospital groups or government healthcare programs could substantially increase distribution volumes, tapping into China's vast and fragmented pharmaceutical distribution market.
- Growth opportunity 4: Capitalizing on the Growing Demand for Traditional Chinese Medicine (TCM). China BCT Pharmacy Group, Inc. already includes traditional Chinese medicines and herbal remedies in its inventory and retail offerings. With increasing government support and consumer preference for TCM, there is a significant opportunity to expand this segment. This could involve developing new TCM products, enhancing the sourcing and processing of high-quality herbal ingredients, or establishing specialized TCM clinics within its 'Baicaotang' pharmacies. The global TCM market is projected to grow significantly, with China being the largest contributor, offering a substantial growth avenue for CNBI over the next 5-10 years.
- Growth opportunity 5: Leveraging E-commerce and Digital Healthcare Platforms. While not explicitly stated, the company's comprehensive product range and retail presence provide a strong foundation for entering or expanding into online pharmaceutical sales and digital healthcare services. The rapid growth of e-commerce in China, particularly for healthcare products, presents an opportunity to reach a broader consumer base beyond physical pharmacy locations. Developing an robust online platform for prescription and OTC drug delivery, alongside virtual consultations or health management services, could unlock new revenue streams and enhance customer convenience, aligning with the digital transformation trends in the healthcare sector over the coming years.
What Opportunities Does CNBI Have?
- Growing demand for pharmaceutical products in China driven by an aging population and increasing healthcare expenditure.
- Potential to expand the 'Baicaotang' retail pharmacy network into new geographic regions within China.
- Diversification of pharmaceutical manufacturing into new therapeutic areas or development of new generic drugs.
- Leveraging e-commerce and digital healthcare platforms to reach a broader consumer base.
- Capitalizing on increasing consumer preference and government support for Traditional Chinese Medicine (TCM).
What Threats Does CNBI Face?
- Intense competition from larger domestic and international pharmaceutical companies in China.
- Stringent and evolving regulatory environment in the Chinese pharmaceutical sector.
- Risk of delisting from the OTC market due to non-compliance or failure to meet requirements.
- Limited access to capital for expansion and R&D due to its micro-cap status and OTC listing.
- Economic downturns or changes in consumer spending habits impacting retail pharmacy sales.
What Are CNBI's Competitive Advantages?
- Integrated business model encompassing distribution, retail, and manufacturing, providing control over the supply chain.
- Extensive retail network of 196 'Baicaotang' pharmacies, establishing direct consumer touchpoints and brand recognition in Guangxi province.
- Diverse product portfolio of approximately 8,000 items, catering to a broad spectrum of medical and healthcare needs.
- Proprietary manufacturing capabilities under the 'Asio' brand for generic and clinical pharmaceuticals, offering product differentiation.
- Established presence and operational experience within the People's Republic of China's pharmaceutical market.
What Does CNBI Do?
China BCT Pharmacy Group, Inc. functions as a comprehensive pharmaceutical enterprise within the People's Republic of China, conducting its operations through various subsidiary companies. The company's business activities are primarily categorized into three distinct divisions: Pharmaceutical Distribution, Retail Pharmacy, and Pharmaceutical Manufacturing. The Pharmaceutical Distribution division is responsible for procuring a diverse array of medicinal goods from various suppliers, subsequently supplying them to a broad client base that includes hospitals, retail drug stores, other wholesale distributors, clinics, medical centers, and individual consumers. Its extensive inventory, numbering approximately 8,000 distinct items, encompasses both branded and generic prescription medications, over-the-counter remedies, traditional Western and Chinese medicines, personal care products, medical supplies, Chinese herbal remedies, and medical instruments. Through its Retail Pharmacy segment, the company manages a network of 196 directly owned pharmacies, predominantly located in Guangxi province, operating under the 'Baicaotang' brand. These outlets provide expert pharmaceutical services and offer a broad assortment of health-related products, including prescription and non-prescription drugs, refined and roughly processed traditional Chinese herbal medicines, family planning items, and various other pharmaceutical and healthcare products. The Pharmaceutical Manufacturing division, operating under the 'Asio' brand, is responsible for producing and marketing a range of generic and clinical pharmaceuticals, including treatments for inflammation and bacterial infections, oncology drugs, cardiovascular medications, and hepatitis therapies. Key products manufactured by the company include Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company was originally known as China Baicaotang Medicine Limited before adopting its current name in March 2010, with its corporate headquarters situated in Liuzhou, People's Republic of China.
What Products and Services Does CNBI Offer?
- Operates as a comprehensive pharmaceutical enterprise in the People's Republic of China.
- Engages in Pharmaceutical Distribution, supplying approximately 8,000 diverse medicinal goods to various clients.
- Manages a Retail Pharmacy segment with 196 directly owned 'Baicaotang' pharmacies, primarily in Guangxi province.
- Conducts Pharmaceutical Manufacturing under the 'Asio' brand, producing generic and clinical pharmaceuticals.
- Manufactures key products including Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection.
- Offers a broad inventory including branded and generic prescription medications, OTC remedies, Western and Chinese medicines, and medical supplies.
- Provides expert pharmaceutical services and a wide assortment of health-related products through its retail outlets.
How Does CNBI Make Money?
- Procures medicinal goods from suppliers and distributes them to hospitals, clinics, retail drug stores, and other distributors.
- Generates revenue through direct sales of prescription and non-prescription drugs, traditional Chinese medicines, and healthcare products via its 'Baicaotang' retail pharmacy network.
- Manufactures and markets its own range of generic and clinical pharmaceuticals under the 'Asio' brand to various healthcare providers and distributors.
- Leverages an extensive inventory of approximately 8,000 distinct items to cater to diverse customer needs across its distribution and retail channels.
- Operates an integrated supply chain model, combining sourcing, manufacturing, wholesale, and direct-to-consumer retail to capture value at multiple points.
What Industry Does CNBI Operate In?
China BCT Pharmacy Group, Inc. operates within China's dynamic and expanding pharmaceutical industry, which is characterized by increasing healthcare expenditure and a large, aging population driving demand for both traditional and modern medicines. The company's integrated model, encompassing distribution, retail, and manufacturing, positions it across multiple segments of the pharmaceutical value chain. While the industry benefits from government support for healthcare reforms and drug innovation, it also faces intense competition from both domestic and international players, as well as stringent regulatory oversight. CNBI's focus on a broad inventory of approximately 8,000 items, including Western, Chinese, and OTC medicines, allows it to cater to diverse consumer needs, particularly within its primary geographic focus of Guangxi province. The market trend indicates a shift towards greater accessibility and affordability of pharmaceuticals, which CNBI's retail pharmacy network aims to address.
Who Are CNBI's Key Customers?
- Hospitals and clinics seeking a wide range of pharmaceutical products for patient care.
- Retail drug stores and other wholesale distributors requiring a diverse inventory of medicines and healthcare items.
- Individual consumers purchasing prescription drugs, over-the-counter remedies, and health-related products from 'Baicaotang' pharmacies.
- Medical centers and other healthcare institutions procuring medical supplies and instruments.
- Patients requiring specific generic and clinical pharmaceuticals manufactured by the 'Asio' division.
Company Profile
China BCT Pharmacy Group, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Liuzhou, CN. The company is led by CEO Huitian Tang. CNBI has traded publicly since 2010.
F-Score 4/9Financial Health
China BCT Pharmacy Group, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.34 places it in the grey zone, a middle ground that warrants monitoring.
ROE 17%Key Financial Metrics
Return on equity for China BCT Pharmacy Group, Inc. stands at 16.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.6%, showing how much profit it generates from its asset base. CNBI trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 2.72 indicates the company holds enough short-term assets to cover its near-term obligations.
CNBI Valuation & Market Position
With a 687K market cap, China BCT Pharmacy Group, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CNBI's quantitative score of 41/100 is below the peer average of 59/100.
CNBI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in CNBI's future, signaling potential undervaluation.
- The community is buzzing about CNBI's expansion into new markets, hinting at growth opportunities.
- Positive sentiment is building around CNBI's innovative approach to pharmaceutical distribution.
- Market perception is shifting, with CNBI being viewed as a disruptor in the traditional pharmacy space.
Bear Case
- Some insiders have recently sold shares, potentially indicating concerns about short-term performance.
- Community discussions reveal worries about increased competition in CNBI's core market.
- Bearish sentiment is emerging due to regulatory uncertainties impacting the pharmaceutical sector.
- Market perception includes skepticism about CNBI's ability to scale its operations effectively.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CNBI Latest News
No recent news available for CNBI.
CNBI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNBI.
Price Targets
Wall Street price target analysis for CNBI.
CNBI MoonshotScore
What does this score mean?
The MoonshotScore rates CNBI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Huitian Tang
CEO
Huitian Tang serves as the Chief Executive Officer of China BCT Pharmacy Group, Inc., overseeing a significant workforce of 1,677 employees. His leadership is central to the company's operations across its three primary divisions: Pharmaceutical Distribution, Retail Pharmacy, and Pharmaceutical Manufacturing. While specific details on his prior career history and educational background are not provided in the available data, his role as CEO indicates a position of significant responsibility in managing a comprehensive pharmaceutical enterprise within the People's Republic of China.
Track Record: Under Huitian Tang's leadership, China BCT Pharmacy Group, Inc. continues to operate its integrated pharmaceutical business model, encompassing 196 'Baicaotang' branded pharmacies and the 'Asio' manufacturing division. His tenure has seen the company maintain its diverse inventory of approximately 8,000 items and serve a broad client base across the healthcare supply chain in China. The company's consistent operational structure and presence in the market reflect ongoing management of its core business segments.
CNBI OTC Market Information
China BCT Pharmacy Group, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike stocks listed on major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements regarding financial standards, corporate governance, and disclosure, OTC Other companies have minimal or no public disclosure requirements. This tier is typically for companies that are not current in their reporting, are in financial distress, or have limited public information, making them highly speculative and difficult to research. Investors should be aware of the significantly higher risks associated with this tier compared to regulated exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Heightened risk of delisting from the OTC market due to non-compliance with minimal requirements or lack of financial reporting.
- Extremely limited liquidity and wide bid-ask spreads, making it difficult to buy or sell shares without significantly impacting the price.
- Lack of comprehensive and timely financial disclosure, leading to limited transparency and difficulty in assessing the company's true financial health.
- Increased susceptibility to market manipulation due to low share price, low volume, and minimal regulatory oversight.
- Limited access to capital markets for financing growth or operational needs, hindering future development.
- Verify the company's most recent financial statements and disclosures, if any are available, directly from the OTC Markets website or company filings.
- Research the background and track record of management beyond what is publicly stated, given the limited disclosure requirements.
- Thoroughly understand the company's business model, revenue streams, and competitive landscape within the Chinese pharmaceutical market.
- Assess any news releases or corporate actions for indications of operational developments or financial viability.
- Evaluate the company's regulatory compliance status and any potential legal or operational challenges.
- Consider the potential for significant share price volatility and the challenges associated with exiting an investment in an OTC Other stock.
- Investigate any potential red flags or warnings issued by regulatory bodies regarding the company or its trading activities.
- Operates a network of 196 directly owned pharmacies under the 'Baicaotang' brand.
- Engages in pharmaceutical manufacturing under the 'Asio' brand, producing specific generic and clinical drugs.
- Maintains an extensive inventory of approximately 8,000 distinct items across its distribution and retail segments.
- Employs a substantial workforce of 1,677 individuals, indicating active and ongoing operations.
- Has a physical corporate headquarters located in Liuzhou, People's Republic of China.
Common Questions About CNBI (Healthcare)
What does China BCT Pharmacy Group, Inc. do?
China BCT Pharmacy Group, Inc. operates as a comprehensive pharmaceutical enterprise in the People's Republic of China, structured into three core divisions. Its Pharmaceutical Distribution segment procures and supplies a vast array of approximately 8,000 medicinal items to hospitals, clinics, and other distributors. The Retail Pharmacy division manages 196 'Baicaotang' branded pharmacies, primarily in Guangxi province, offering prescription and OTC drugs, traditional Chinese medicines, and healthcare products directly to consumers. Additionally, its 'Asio' brand focuses on Pharmaceutical Manufacturing, producing generic and clinical drugs for various therapeutic areas, including inflammation, infections, oncology, cardiovascular, and hepatitis.
What are the key growth opportunities for CNBI in the Chinese healthcare market?
CNBI has several growth opportunities within the Chinese healthcare market. These include the potential to expand its 'Baicaotang' retail pharmacy network beyond Guangxi province into other growing urban centers, capitalizing on increasing consumer demand for accessible healthcare. Further diversification and enhancement of its 'Asio' pharmaceutical manufacturing capabilities, possibly through new product development or strategic partnerships, could also drive growth. Additionally, broadening its pharmaceutical distribution reach and client base, as well as leveraging the increasing consumer preference for Traditional Chinese Medicine (TCM) by expanding its offerings in this segment, represent significant avenues for future expansion within China's dynamic healthcare landscape.
What are the primary risks associated with investing in CNBI, particularly given its OTC listing?
Investing in China BCT Pharmacy Group, Inc. carries significant risks, largely amplified by its 'OTC Other' listing. This tier implies minimal disclosure, leading to an 'Unknown' disclosure status and limited transparency for investors. The company faces a heightened risk of delisting and extremely limited liquidity, making it challenging to buy or sell shares. Its micro-cap status, with a market capitalization of $686,778 and a share price of $0.0002, suggests limited financial resources and increased susceptibility to price volatility. Furthermore, the company operates in a highly competitive and regulated Chinese pharmaceutical market, adding to operational and regulatory risks.
How does China BCT Pharmacy Group, Inc. differentiate its product offerings in the pharmaceutical market?
China BCT Pharmacy Group, Inc. differentiates its product offerings through an integrated business model that spans distribution, retail, and manufacturing, allowing for comprehensive market coverage. Its Pharmaceutical Distribution division offers an extensive inventory of approximately 8,000 distinct items, including both Western and traditional Chinese medicines, catering to a broad client base. The 'Baicaotang' retail pharmacy network provides direct consumer access and expert pharmaceutical services. Crucially, the 'Asio' manufacturing division produces its own range of generic and clinical pharmaceuticals, such as Levodopa and oncology drugs, providing proprietary products that complement its distributed and retail offerings, thus creating a diversified and integrated product ecosystem within the Chinese healthcare sector.
What are the key factors to evaluate for CNBI?
China BCT Pharmacy Group, Inc. (CNBI) holds an AI score of 41/100 (low). Not financial advice.
How frequently does CNBI data refresh on this page?
CNBI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CNBI's recent stock price performance?
China BCT Pharmacy Group, Inc. (CNBI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive pharmaceutical enterprise with three distinct divisions: distribution, retail, and manufacturing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNBI overvalued or undervalued right now?
Valuing China BCT Pharmacy Group, Inc. (CNBI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.